We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Single Metagenomic Next-Generation Sequencing Test Can Detect All Infectious Pathogens

By LabMedica International staff writers
Posted on 12 Nov 2024
Print article
Image: The clinical laboratory workflow for mNGS (Photo courtesy of UCSF)
Image: The clinical laboratory workflow for mNGS (Photo courtesy of UCSF)

Metagenomic next-generation sequencing (mNGS) is a comprehensive sequencing method that analyzes all nucleic acids (DNA and RNA) in a clinical sample at high depth, generating 10-20 million sequences per sample. This approach can be applied to any type of clinical sample, including cerebrospinal fluid, plasma, respiratory secretions, urine, stool, or tissue. Now, mNGS offers the potential to diagnose a wide range of infectious agents—viruses, bacteria, fungi, and parasites—through a single test.

Researchers at the UCSF Center for Next-Gen Precision Diagnostics (San Francisco, CA, USA) have developed an mNGS test capable of detecting sequence reads for all pathogens, helping to identify the cause of an infection. Initially, the UCSF team developed an mNGS test to identify pathogens in cerebrospinal fluid for meningitis and encephalitis diagnosis. This was followed by the development of a clinical plasma mNGS test designed to detect DNA viruses, bacteria, fungi, and parasites responsible for sepsis and disseminated infections in other organs. To analyze mNGS data quickly for pathogen identification, the team employs SURPI+ (SURPI PLUS), a clinical bioinformatics software pipeline.

In research published in Nature Medicine, the team demonstrated that their mNGS test for cerebrospinal fluid accurately identified 86% of neurological infections. They are now working on validating clinical tests for detecting all microorganisms (bacteria, viruses, fungi, and parasites) causing pneumonia in respiratory fluids like bronchoalveolar lavage or tracheal aspirates. Additionally, in a related study published in Nature Communications, the team used mNGS to identify pneumonia-causing pathogens in respiratory fluids and automated the process to generate faster results.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.